Daiichi Sankyo
Michael A. Grosso MD, FACS currently serves as the Vice President and Global Head of Clinical Development for Specialty Medicine at Daiichi Sankyo, Inc., a position held since December 2010, having previously advanced through roles including Executive Director of Cardiovascular Clinical Development. Additionally, Michael A. Grosso is an Advisory Board Member at Perosphere Technologies. Prior experience includes serving as Director of Medical Advisor for Cardio/Thrombosis at sanofi-aventis and holding academic and clinical roles at the University of Pennsylvania and UMDNJ/Cooper University. Michael A. Grosso earned an MD from the University of Pennsylvania School of Medicine and a BS in Biology from the University of the Sciences in Philadelphia.
This person is not in any teams
This person is not in any offices
Daiichi Sankyo
21 followers
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Daiichi Sankyo Group and Ranbaxy Group. The Daiichi Sankyo Group segment comprises of Daiichi Sankyo Co., Ltd. and its subsidiaries. The Ranbaxy Group segment includes its core company, Ranbaxy Laboratories Ltd. Both group segments deal with business activities in prescription drugs and general pharmaceutical products. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.